Compare Inovio Pharmaceuticals Inc (INO) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.71. Which is the better fit depends on your goals.
| INO | VCIT | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Fixed Income |
52-Week High | $2.87 | $84.82 |
52-Week Low | $1.05 | $81.45 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
VCIT trades at $81.71, down 0.28% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts of $0.33-$0.34, reflecting its income-focused strategy. News coverage highlights VCIT's competitive expense ratio of 0.03% and yield advantages over peers like VGIT and IEI, though technical indicators suggest near-term pressure with support clustered around $82.
The outlook balances VCIT's low-cost access to intermediate-term corporate bonds against interest rate sensitivity and economic cycle risks. Current bearish momentum warrants caution, but the fund's structural efficiency and yield appeal position it for income investors seeking diversified credit exposure amid fluctuating fixed-income conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
